Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 2 Different Transdermal Doses of Rotigotine in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome.

Next Previous
X
Search
Trial Profile

A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 2 Different Transdermal Doses of Rotigotine in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Fibromyalgia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Schwarz Pharma AG; UCB

    • Most Recent Events

    • 20 Feb 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
    • 20 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Dec 2008 Planned end date changed from 1 Oct 2008 to 1 May 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top